The semaglutide access landscape changed significantly on February 21, 2026, when the FDA officially declared the semaglutide shortage resolved — removing all Ozempic and Wegovy formulations from the drug shortage list. That single regulatory decision ended most of the compounding access that had made semaglutide available at $150–350/month through telehealth platforms since 2023. Enforcement discretion for 503A pharmacies ended April 22, 2026. For 503B outsourcing facilities, it ended May 22, 2026 (FDA guidance, 2026).
If you're asking where to buy semaglutide in 2026, the honest answer is shorter and more restrictive than it was six months ago. But there are still legitimate pathways — and understanding what's actually legal versus what vendors continue to sell without clear compliance is the most important thing before you buy.
Key Takeaways
- —The FDA declared the semaglutide shortage over February 21, 2026 — compounding enforcement for 503A pharmacies started April 22, with narrow exceptions for patients with specific clinical needs.
- —Legal options in 2026: brand-name Ozempic/Wegovy with a prescription, Novo Nordisk manufacturer programmes, or compounded semaglutide for specific patient needs (allergy to excipients, unique dose requirements).
- —The SURMOUNT-5 72-week head-to-head trial showed semaglutide 13.7% weight loss vs. tirzepatide's 20.2% — the comparison matters if you're choosing between GLP-1 options.
- —Compare semaglutide against tirzepatide using the Next Pep comparison tool before your consultation.
The FDA's shortage list status governed whether compounding was permitted under sections 503A and 503B of the Food, Drug, and Cosmetic Act. When a drug is on the shortage list, compounding pharmacies can legally prepare it to help meet supply gaps. When the shortage is declared resolved, that exception disappears.
There is one remaining legal compounding exception: pharmacies can still prepare compounded semaglutide if it's "not essentially a copy" — meaning it includes a clinically meaningful difference that addresses a specific patient need. Examples include formulations for patients with allergies to excipients in the branded product, different concentrations for specific dosing needs, or combination formulations with other clinically indicated components. General-purpose compounded semaglutide for weight management no longer qualifies (Burr & Forman, 2026).
1. Brand-name Ozempic (type 2 diabetes indication). Ozempic is FDA-approved for glycaemic control in type 2 diabetes. It's also widely used off-label for weight management — legal under physician discretion, though insurance coverage for this use varies significantly. List price approximately $935/month; with insurance or manufacturer coupons, significantly less.
2. Brand-name Wegovy (weight management indication). Wegovy is FDA-approved for chronic weight management. List price approximately $1,350/month. Insurance coverage has improved since 2023 but remains inconsistent. Novo Nordisk's NovoCare programme offers savings for qualifying patients.
3. Rybelsus (oral semaglutide). The oral formulation, FDA-approved for type 2 diabetes, provides access to semaglutide without injection. Bioavailability is significantly lower than subcutaneous administration (~1% absorption vs. ~89% for subcutaneous), requiring the 3 mg → 7 mg → 14 mg dose escalation to achieve therapeutic levels. Not equivalent to subcutaneous Wegovy at matched doses.
4. Compounded semaglutide for specific clinical needs. This narrow exception remains available through 503A pharmacies. If you have documented excipient allergies (e.g., to the polysorbate 80 in Ozempic/Wegovy), require an unusual dose that isn't commercially available, or have another specific clinical need, a prescribing physician can justify compounding on that basis. The pharmacy must be able to articulate the clinical distinction clearly.
If you're deciding between semaglutide and tirzepatide — the two dominant GLP-1 options in 2026 — the SURMOUNT-5 trial is the most important piece of data. This 72-week randomised controlled trial directly compared maximum-dose tirzepatide (20 mg) against maximum-dose semaglutide (2.4 mg) in adults with obesity: tirzepatide produced 20.2% mean weight loss vs. semaglutide's 13.7% (NEJM, 2025).
That's a meaningful difference in a head-to-head RCT — the kind of evidence rarely available in this field. Tirzepatide's dual GIP/GLP-1 mechanism produces more weight loss on average. Whether that difference matters for any individual patient depends on their response, tolerance, and cost/access situation.
Semaglutide has a longer post-marketing track record — it's been in widespread clinical use since 2021 vs. tirzepatide's 2022. Its cardiovascular outcome data (SUSTAIN, SELECT trial) is more extensive. For patients with cardiovascular risk, the published semaglutide CV data may be the more important consideration than the weight differential.
The Next Pep comparison tool puts semaglutide and tirzepatide side by side with mechanism, pharmacokinetics, and dosing data to support that decision before your prescriber consultation.
If you have a documented clinical need that qualifies for compounded semaglutide under the narrowed exception, the quality framework remains important.
API source. The active pharmaceutical ingredient must come from an FDA-registered manufacturer. Ask directly; a compliant pharmacy will answer clearly.
Batch-specific COA. HPLC purity and concentration verification for the specific batch dispensed. Semaglutide's molecular weight is 4113.58 Da — this is what mass spectrometry should confirm.
PCAB accreditation. The strongest available quality signal for a 503A pharmacy.
Sterility and endotoxin testing. Semaglutide is subcutaneous — sterility and endotoxin burden matter.
Understanding what semaglutide actually does — dual GLP-1 mechanism, pharmacokinetics, the SURMOUNT-5 head-to-head data against tirzepatide, and what the shortage resolution means for access — makes the prescriber conversation substantially more productive. The peptide library covers both semaglutide and tirzepatide with full molecular and clinical summaries in one neutral, cross-referenced view. Use the comparison tool to put them side-by-side across mechanism, trial data, and dosing — before any platform tells you which one to choose.
For planning your injectable protocol, the dosing calculator handles the reconstitution maths: enter your prescribed concentration and target dose and it returns exact draw volume in mL and syringe units. Next Pep is independent — no telehealth referral, no pharmacy affiliation, no commercial relationship with any compound. It's the research foundation you use before engaging anyone who stands to benefit from your purchase.
Compounded semaglutide became significantly restricted after the FDA's shortage declaration was resolved. General-purpose compounding for weight management is no longer permitted under 503A. Narrow exceptions remain for patients with specific clinical needs: documented excipient allergies, unique dosing requirements, or clinically justified combination formulations. Ask any pharmacy currently compounding semaglutide to explain their specific legal basis — and verify they haven't received an FDA warning letter.
With insurance coverage and a valid prescription, Ozempic or Wegovy co-pays can range from $25 to $200/month through Novo Nordisk's NovoCare savings programme. Without insurance, brand-name costs are approximately $935/month (Ozempic) and $1,350/month (Wegovy). Compounded options are now narrow and reserved for specific clinical needs. For many patients, the cost comparison may now favour tirzepatide via 503A compounding, which remains available at $229–349/month.
The SURMOUNT-5 72-week head-to-head RCT showed tirzepatide producing 20.2% mean weight loss vs. semaglutide's 13.7% at maximum approved doses. Tirzepatide's dual GIP/GLP-1 mechanism appears to produce meaningfully greater weight loss on average. However, cardiovascular outcome data is more extensive for semaglutide, and individual GI tolerability varies independently of average trial results. Use the comparison tool and discuss both options with a prescriber.
Yes — this is one of the qualifying exceptions that remains legal under the "not essentially a copy" standard. If you have a documented allergy to polysorbate 80 or another excipient in the branded formulations, a 503A pharmacy can compound a formulation that excludes that excipient. Your prescriber would need to document the clinical rationale. PCAB-accredited pharmacies are best positioned to handle this properly with the required documentation trail.
This article is for informational purposes only. Semaglutide (Ozempic/Wegovy/Rybelsus) is an FDA-approved prescription medication. Compounding access is now restricted following the end of the drug shortage in February 2026. Consult a licensed healthcare professional before starting any GLP-1 protocol.
Research Disclaimer. All content on Next Pep is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare professional before considering any peptide protocol.
A head-to-head comparison of BPC-157 and TB-500 covering mechanism, tissue specificity, dosing frequency, human evidence, and whether stacking them adds anything the literature actually supports.
Ipamorelin is a ghrelin-receptor agonist; CJC-1295 is a GHRH analog. Their mechanisms are complementary, which is why protocols typically stack them. This guide covers what each does alone, what stacking adds, and the DAC vs non-DAC distinction.